DK0920429T3 - Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater - Google Patents

Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater

Info

Publication number
DK0920429T3
DK0920429T3 DK97929472T DK97929472T DK0920429T3 DK 0920429 T3 DK0920429 T3 DK 0920429T3 DK 97929472 T DK97929472 T DK 97929472T DK 97929472 T DK97929472 T DK 97929472T DK 0920429 T3 DK0920429 T3 DK 0920429T3
Authority
DK
Denmark
Prior art keywords
pyrimido
substituted pyrido
bicyclic derivatives
bicyclic
derivatives
Prior art date
Application number
DK97929472T
Other languages
Danish (da)
English (en)
Inventor
Yuhpyng Liang Chen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK0920429T3 publication Critical patent/DK0920429T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK97929472T 1996-08-06 1997-07-23 Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater DK0920429T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2345396P 1996-08-06 1996-08-06
PCT/IB1997/000918 WO1998005661A1 (en) 1996-08-06 1997-07-23 Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives

Publications (1)

Publication Number Publication Date
DK0920429T3 true DK0920429T3 (da) 2003-05-12

Family

ID=21815208

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97929472T DK0920429T3 (da) 1996-08-06 1997-07-23 Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater

Country Status (41)

Country Link
US (1) US6492520B1 (is)
EP (1) EP0920429B1 (is)
JP (1) JP3345021B2 (is)
KR (1) KR20000029843A (is)
CN (1) CN1093130C (is)
AP (1) AP1096A (is)
AR (1) AR008829A1 (is)
AT (1) ATE232863T1 (is)
AU (1) AU709203B2 (is)
BG (1) BG103143A (is)
BR (1) BR9710808A (is)
CA (1) CA2262692C (is)
CO (1) CO4900060A1 (is)
CZ (1) CZ292806B6 (is)
DE (1) DE69719193T2 (is)
DK (1) DK0920429T3 (is)
DZ (1) DZ2289A1 (is)
EA (1) EA003188B1 (is)
ES (1) ES2191183T3 (is)
GT (1) GT199700089A (is)
HK (1) HK1021734A1 (is)
HR (1) HRP970432B1 (is)
ID (1) ID17980A (is)
IL (1) IL128188A0 (is)
IS (1) IS4948A (is)
MA (1) MA24296A1 (is)
NO (1) NO313293B1 (is)
NZ (1) NZ333727A (is)
OA (1) OA10970A (is)
PA (1) PA8435201A1 (is)
PE (1) PE97098A1 (is)
PL (1) PL331602A1 (is)
SA (1) SA97180334A (is)
SK (1) SK14099A3 (is)
TN (1) TNSN97135A1 (is)
TR (1) TR199900228T2 (is)
TW (1) TW550265B (is)
UY (1) UY24655A1 (is)
WO (1) WO1998005661A1 (is)
YU (1) YU5399A (is)
ZA (1) ZA976954B (is)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO2000027850A2 (en) 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods relating thereto
PT1129091E (pt) 1998-11-12 2003-02-28 Neurocrine Biosciences Inc Antagonistas de receptor de crf e metodos relacionados
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
IL139197A0 (en) 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
AU2001232271A1 (en) * 2000-02-14 2001-08-20 Japan Tobacco Inc. Preventives/remedies for postoperative stress
WO2001062718A1 (fr) * 2000-02-25 2001-08-30 Japan Tobacco, Inc. Dérivé de benzamide et utilisation de celui-ci
MY141144A (en) * 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0011964D0 (en) 2000-05-18 2000-07-05 Suyal N Thick glass films with controlled refractive indices and their applications
MXPA03003612A (es) * 2000-10-23 2003-06-19 Smithkline Beecham Corp Compuestos novedosos.
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
US6677352B1 (en) 2001-09-26 2004-01-13 Yamin Wang 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders
CN1646131A (zh) 2002-04-19 2005-07-27 史密丝克莱恩比彻姆公司 新化合物
FR2846657B1 (fr) * 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MXPA06002608A (es) 2002-12-20 2007-01-23 Pfizer Prod Inc Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
US20050085479A1 (en) * 2003-08-27 2005-04-21 Pharmacia Corporation Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
EP2522670A1 (en) * 2004-04-07 2012-11-14 Takeda Pharmaceutical Company Limited Heterocyclic CRF receptor antagonists
EP1751142A1 (en) 2004-05-14 2007-02-14 Pfizer Products Incorporated Pyrimidines derivatives for the treatment of abnormal cell growth
CA2564199A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
EP1756090A1 (en) 2004-05-14 2007-02-28 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
WO2006104917A2 (en) * 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives
AR053346A1 (es) * 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
PE20061193A1 (es) * 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
EP1868612A4 (en) * 2005-03-25 2010-03-24 Glaxo Group Ltd NOVEL CONNECTIONS
EP1888548B1 (en) 2005-05-26 2012-08-22 Neuron Systems, Inc Quinoline derivative for the treatment of retinal diseases
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
AU2006330924B2 (en) 2005-12-21 2012-03-15 Abbvie Inc. Anti-viral compounds
RU2467007C2 (ru) 2005-12-21 2012-11-20 Эбботт Лэборетриз Производные [1,8]нафтиридина, полезные в качестве ингибиторов репликации вируса hcv
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
TWI399380B (zh) 2006-12-20 2013-06-21 Abbott Lab 抗病毒化合物
TW201639852A (zh) 2008-12-09 2016-11-16 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
WO2010096426A2 (en) * 2009-02-20 2010-08-26 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
PL2477987T3 (pl) 2009-09-14 2018-06-29 Gilead Sciences, Inc. Modulatory receptorów toll-podobnych
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CN107383009B (zh) 2012-06-13 2020-06-09 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SG11201508328PA (en) 2013-04-19 2015-11-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
PT3143025T (pt) * 2014-05-15 2019-12-03 Hoffmann La Roche Compostos para tratamento da atrofia muscular espinhal
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
MX2017000026A (es) 2014-07-11 2017-05-01 Gilead Sciences Inc Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
ES2845205T3 (es) 2014-09-16 2021-07-26 Gilead Sciences Inc Métodos para preparar moduladores de receptores tipo Toll
SI3194401T1 (sl) 2014-09-16 2020-12-31 Gilead Sciences, Inc. Trdne oblike modulatorja toličnega receptorja
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
CN107438607B (zh) 2015-02-20 2021-02-05 因赛特公司 作为fgfr抑制剂的双环杂环
EP3317278B1 (en) 2015-07-01 2021-04-14 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
AU2016311158A1 (en) 2015-08-21 2018-04-05 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
ES2913423T3 (es) 2016-02-12 2022-06-02 Cytokinetics Inc Derivados de tetrahidroisoquinolina
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3658560A4 (en) 2017-07-25 2021-01-06 Crinetics Pharmaceuticals, Inc. SOMATOSTAT IN MODULATORS AND USES THEREOF
AU2018348174A1 (en) * 2017-10-10 2020-04-23 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
AU2019262195B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
CN112714762A (zh) 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途
WO2020068986A1 (en) 2018-09-25 2020-04-02 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
JP2022526917A (ja) 2019-03-26 2022-05-27 アルデイラ セラピューティクス, インコーポレイテッド 眼科用製剤およびその使用
EP3962894A4 (en) 2019-05-02 2023-01-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2022552324A (ja) 2019-10-14 2022-12-15 インサイト・コーポレイション Fgfr阻害剤としての二環式複素環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Fgfr阻害剤としての三環式ヘテロ環

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
ATE177101T1 (de) * 1992-12-17 1999-03-15 Pfizer Pyrrolopyrimidine als crf antagonisten
TW444018B (en) * 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
EP0765327B1 (en) * 1994-06-16 1999-07-21 Pfizer Inc. Pyrazolo and pyrrolopyridines
JP2898887B2 (ja) * 1994-08-31 1999-06-02 沖電気工業株式会社 Icカードの読み取り装置
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases
ATE182148T1 (de) * 1995-05-12 1999-07-15 Neurogen Corp Neue deazapurinderivate; eine neue klasse von crf1-spezifischen liganden
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
DK0778277T3 (da) * 1995-12-08 2003-10-27 Pfizer Substituerede heterocycliske derivater som CRF antagonister
BR9707391A (pt) 1996-02-07 1999-07-20 Janssen Pharmaceutica Nv Pirazolpirimidinas como antagonistas de receptor de crf
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same

Also Published As

Publication number Publication date
IS4948A (is) 1999-01-19
AP1096A (en) 2002-08-26
CN1227552A (zh) 1999-09-01
AU3356397A (en) 1998-02-25
CA2262692A1 (en) 1998-02-12
EP0920429B1 (en) 2003-02-19
TNSN97135A1 (fr) 2005-03-15
GT199700089A (es) 1999-01-26
BR9710808A (pt) 1999-08-17
UY24655A1 (es) 2000-09-29
CO4900060A1 (es) 2000-03-27
YU5399A (sh) 2002-03-18
DE69719193T2 (de) 2003-09-25
EP0920429A1 (en) 1999-06-09
ID17980A (id) 1998-02-12
AP9701052A0 (en) 1997-10-31
PL331602A1 (en) 1999-08-02
DE69719193D1 (de) 2003-03-27
CA2262692C (en) 2002-06-11
TW550265B (en) 2003-09-01
PE97098A1 (es) 1999-01-12
CZ292806B6 (cs) 2003-12-17
CN1093130C (zh) 2002-10-23
ES2191183T3 (es) 2003-09-01
NO313293B1 (no) 2002-09-09
HRP970432B1 (en) 2002-10-31
EA199900083A1 (ru) 1999-08-26
SK14099A3 (en) 2000-05-16
OA10970A (en) 2001-11-05
NZ333727A (en) 2000-09-29
PA8435201A1 (es) 1999-12-27
AR008829A1 (es) 2000-02-23
DZ2289A1 (fr) 2002-12-25
MA24296A1 (fr) 1998-04-01
CZ41199A3 (cs) 2000-01-12
JP3345021B2 (ja) 2002-11-18
TR199900228T2 (xx) 1999-03-22
JP2000501116A (ja) 2000-02-02
AU709203B2 (en) 1999-08-26
ZA976954B (en) 1999-02-05
WO1998005661A1 (en) 1998-02-12
HRP970432A2 (en) 1998-08-31
EA003188B1 (ru) 2003-02-27
NO990544L (no) 1999-03-31
KR20000029843A (ko) 2000-05-25
ATE232863T1 (de) 2003-03-15
SA97180334A (ar) 2005-12-03
HK1021734A1 (en) 2000-06-30
NO990544D0 (no) 1999-02-05
BG103143A (en) 1999-09-30
IL128188A0 (en) 1999-11-30
US6492520B1 (en) 2002-12-10

Similar Documents

Publication Publication Date Title
DK0920429T3 (da) Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater
IS4963A (is) Setnar 6,5-heteró-bísýklískar afleiður
DK0925298T3 (da) Substituerede 6,6-heterobicykliske derivater
PT901474E (pt) Derivados de aril-pirimidina.
DK1000048T3 (da) Substituerede 1,2,3,4-tetrahydronapthalenderivater
DE69718771D1 (de) Substituierte 1,2,3,4-tetrahydronaphthalinderivate
TR27961A (tr) Sübstitüe edilmis 1,2,3,4 -tetrahidro-5-nitro-pirimidinler.
DK1015467T3 (da) 6,9-brobundne erythromycinderivater
ATE246199T1 (de) 3-descladinose-2,3-anhydroerythromycin-derivate
TR199802520A3 (tr) 1,3,8-Triaza-spiro(4,5) dekan -4-on türevleri.
DE69814441D1 (de) 6,11-verbrückte erythromycinderivate
NL1005675A1 (nl) Polytriazinederivaten-bevattende polyalkylpiperidinyloxy- of polyalkylpiperidinylaminogroepen.
TR199700219A3 (tr) 1,25-Dihidroksi-16, 22, 23-Trisdihidro-kolkalsiferol türevleri.
TR199700927A3 (tr) N-Benzilazolyum türevleri.
SI0920429T1 (en) Substituted pyrido- or pyrimido-containing 6,6- or 6,7-bicyclic derivatives
FI962118A0 (fi) Foerbaettrad anordning foer behandling av roekgaser, saerskilt avgaser
ES1033065Y (es) Conjunto canula-tapa, perfeccionado.
ES1034802Y (es) Tope convertible en percha.
ITRC960004A1 (it) Vergafa m.c.